Back to News
Market Impact: 0.35
Moderna Returns To Q3 Profit; Raises FY26 Outlook On Vaccine Sales And Pipeline Progress
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Moderna returned to profitability in Q3 2026 as revenue rose 29% year over year to $1.3 billion. The report provides no further earnings figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
MRNA0.65
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Stocks making the biggest moves midday: Nvidia, Moderna, IonQ, Airbnb, Firefly Aerospace & more
- While biotech bets swing on trial data, this dividend payer gained 72% since 2024
- 5 Things Investors Need to Know About Friday's Markets
- Our top 10 things to watch in the stock market Friday
- Stocks making the biggest moves premarket: Moderna, Airbnb, Cloudflare, Affirm & more